Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2021-08-20 Earnings Release
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA: Second quarter 2021 result presentation
Earnings Release Classification · 99% confidence The document explicitly states it is the "Second quarter 2021 result presentation" and provides key highlights for Q2 2021, including clinical trial updates and financial metrics (operating expenses, cash flow) for the quarter. This content strongly suggests a periodic financial report. Since it is a comprehensive report for a period shorter than a year (Q2), the appropriate classification is Interim / Quarterly Report (IR). Although it mentions a presentation, the core content provided is the summary of the results, not just an announcement of the report's availability, thus distinguishing it from RPA or RNS. Q2 2021
2021-08-20 English
Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma
Earnings Release Classification · 100% confidence The document is a press release announcing positive topline results from a Phase I clinical trial for a cancer vaccine (UV1). It details response rates, survival data, and mentions that further discussion will occur during the Q2 2021 financial results presentation. The text is a direct announcement of clinical/scientific progress, not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a specific management discussion (MDA). Since it is an announcement of scientific/clinical progress that is material to investors, and it is not explicitly covered by other codes (like ER for financial results highlights, or CT for a call transcript), it fits best under the general 'Regulatory Filings' (RNS) category as a material, non-standard announcement, or potentially an 'Earnings Release' (ER) if the context implies this is the primary way they release such data alongside financials. However, given the focus is purely on clinical trial data rather than financial metrics, RNS is the most appropriate general regulatory announcement category for this type of material update that isn't a standard financial report. Q2 2021
2021-08-12 English
Ultimovacs ASA: Invitation to second quarter 2021 results webcast presentation
Report Publication Announcement Classification · 98% confidence The document is an invitation from Ultimovacs ASA regarding their 'second quarter 2021 results webcast presentation' scheduled for August 20, 2021. It explicitly states that the 'report and presentation will be available on the company website from 08:00 CET the same day.' Since the document itself is an announcement about the publication of results/presentation rather than the full results or the presentation itself, and given its short length (1357 chars), it fits the definition of a Report Publication Announcement (RPA). It is announcing when the Q2 results (which would likely be an ER or IR) and the associated presentation will be released.
2021-08-11 English
Ultimovacs announces first patient enrolled in Phase II FOCUS trial of UV1 in head-and-neck cancer
Regulatory Filings Classification · 99% confidence The document is a press release dated August 5, 2021, announcing that the first patient has been enrolled in the Phase II FOCUS clinical trial for the UV1 vaccine. It details the trial design, endpoints, and expected topline data readout (2023). The text concludes with a statement that the information is considered inside information subject to EU Market Abuse Regulation and was published as a 'stock exchange announcement'. This type of immediate, material, non-financial operational update, especially when framed as a regulatory disclosure (like an RNS in European markets), fits best under the general 'Regulatory Filings' category (RNS) or potentially an 'Earnings Release' (ER) if it were financial, but since it is purely operational/clinical news, RNS is the most appropriate general regulatory disclosure category, as it is not a formal financial report (10-K, IR, ER) or a specific announcement like DIRS or DIV. Given the options, RNS serves as the best fit for a general regulatory news announcement.
2021-08-05 English
Ultimovacs' Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines
Environmental & Social Information Classification · 99% confidence The document is an announcement from Ultimovacs ASA regarding the publication of a review article in 'Frontiers in Immunology' that highlights telomerase-based therapeutic cancer vaccines, including their lead candidate UV1. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about external scientific literature relevant to the company's technology and clinical pipeline. Since it is an announcement about scientific/research progress and does not fit neatly into the specific categories like ER, IR, or CAP, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for miscellaneous corporate announcements that are not otherwise classified, especially those related to research updates or external publications.
2021-07-05 English
Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program
Earnings Release Classification · 99% confidence The document announces clinical trial data (Phase I results for UV1/pembrolizumab combination in advanced melanoma) presented at the ASCO 2021 Annual Meeting. It details efficacy rates (ORR, CR), safety profile, and future clinical plans (Phase II expansion). This content is characteristic of an initial release of periodic financial/operational results, focusing on key performance indicators (clinical trial outcomes) rather than a comprehensive annual report (10-K) or a detailed management discussion (MDA). Since it is the initial announcement of results, it fits best under the Earnings Release (ER) category, which often covers significant operational milestones like positive clinical data for biotech/pharma companies, even if not strictly quarterly earnings. It is not a transcript (CT), a full report (IR/10-K), or a presentation (IP), but rather the press release announcing the findings. Q2 2021
2021-06-04 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.